Title : A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.

Pub. Date : 2013 Jul

PMID : 23591401






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 OBJECTIVES: Sorafenib, an oral multikinase inhibitor of the VEGFR/PDGFR/Raf/MEK/ERK pathway, has shown potential activity in patients with recurrent ovarian cancer (OC). Sorafenib zinc fingers and homeoboxes 2 Homo sapiens